Weeding Through the Peptide Craze:The Good, the Bad, and the Ugly — What Every Chiropractor Should Know

Walk into almost any medical conference today, and you’ll hear the same word repeated over and over again:

Peptides.

Open social media, and they’re everywhere. One peptide melts fat. Another builds muscle. One repairs joints. Yet another promises better sleep, sharper thinking, faster recovery, healthier skin, and a longer life.

The excitement is understandable. 

Peptides represent one of the fastest-growing areas in regenerative and longevity medicine. The global peptide therapeutics market is projected to climb from roughly $164 billion in 2026 to nearly $295 billion by 2033—an increase of almost 80 percent in just seven years. 

Unfortunately, peptide therapies are also one of the most misunderstood.

Doctors are increasingly seeing patients who arrive with questions about peptide injections they’ve seen online or treatments being offered at local wellness clinics. Some are spending thousands of dollars on therapies they barely understand. Others assume that because something is called a peptide, it must be both safe and effective.

Neither assumption is true.

“You don’t need to use peptides in your practice. But you need to know enough about them to answer your patients’ questions intelligently.”

The challenge for chiropractors is learning how to separate science from salesmanship.

First, What Exactly Is a Peptide?

Simply put, peptides are short chains of amino acids, the same building blocks that make up proteins.

Unlike vitamins or herbal extracts, many peptides naturally occur inside the body, where they function as biological messengers. They help cells communicate, influence inflammation, regulate hormones, coordinate tissue repair, and maintain countless physiological processes.

That signaling ability is what makes peptides so intriguing. Rather than forcing the body to respond the way many drugs do, some peptides enhance communication within existing biological pathways. It’s a fundamentally different approach and the epitome of medicine’s motto, “first, do no harm.”

The Good: Real Science

Researchers are studying peptides in laboratory studies, animal models, and, for some applications, human clinical trials.

Particularly exciting is that certain peptides may influence multiple systems simultaneously. Rather than targeting a single symptom, they support broader physiologic processes involved in recovery and resilience.

For chiropractors focused on conservative, patient-centered care, that systems-based approach is especially appealing. 

So where do you start? 

I put peptides into three categories. The first is FDA-approved peptide drugs.

FDA-Approved Peptide Medicine

These are peptide-based drugs that have undergone FDA approval for specific indications. They have defined formulations, manufacturing standards, dosing, labeling, safety information, and clinical evidence supporting their approved use. Examples include:

• Semaglutide — GLP-1 receptor agonist (Ozempic and Wegovy). 
• Liraglutide — another GLP-1 receptor agonist. 
• Teriparatide — parathyroid hormone analog used for osteoporosis. 
• Glucagon — used to treat severe hypoglycemia. 
• Calcitonin — peptide hormone with approved drug formulations. 

The second category is emerging peptides.

 Emerging Peptides: FDA Advisory Committee “Recommended” 

These peptides have recently moved from the fringes of longevity medicine into a serious regulatory debate. 

In July 2026, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) considered seven increasingly popular peptides for potential inclusion on the federal 503A Bulk Drug Substances List. That’s the list that permits state-licensed pharmacies and physicians operating under Section 503A to compound drugs from certain substances. 

The committee recommended six of the seven for inclusion. 

As of this writing, none of these have been included in the bulk list or received FDA approval.

It’s important to distinguish FDA approval from clinical use. Compounded medications are not FDA-approved drugs and operate under a different regulatory framework, subject to applicable federal and state requirements. 

In my medical practice, I have experience with several emerging peptide therapies with great success, and I first approached them as I would any evolving therapy, by carefully considering the available evidence, its limitations, product quality, patient-specific risks and benefits, and the applicable regulatory requirements.

The Bad: Quality Matters 

The third category isn’t for individual peptides, but for peptide products themselves.

The internet has become flooded with peptides. Patients frequently assume they’re purchasing pharmaceutical-grade compounds when they have no reliable way to know what’s inside.

That’s a serious concern, not just for effectiveness, but for safety.

Whenever patients ask about peptide therapy, one of the most important questions isn’t “Which peptide?” It’s “Where did it come from?”

With peptides, the molecule is only part of the equation. Manufacturing, purity, potency, storage, formulation, and route of administration all matter. A peptide with fascinating research behind it isn’t very useful if the product in the patient’s hand isn’t what the label says it is.

The Ugly: Marketing Outpaced Science

“Regenerates cartilage.” “Heals tendons.” “Reverses aging.” “Melts fat.” “Repairs the brain.” 

Those may make compelling marketing claims, but responsible clinicians need to distinguish biological plausibility and preliminary findings from outcomes established in clinical settings. 

Four Ways Chiropractors Can Add Real Value with Peptides

1. Educate Yourself 

When you hear about a peptide, ask: Is the proposed benefit supported by clinical evidence?

2. Ask Patients What They’re Already Taking

Don’t wait for patients to volunteer the information. Add peptides to the conversation along with medications and supplements. Ask specifically:

• Are you currently using any peptides?
• Who recommended or prescribed them?
• Where are you getting them?
• What are you taking them for?

3. Help Patients Evaluate the Source

Discourage patients from purchasing peptides simply because they’re inexpensive or easily accessible. Teach patients to be suspicious of sources that promise miracle results, don’t clearly identify where the medication was produced, or encourage patients to determine their own dosing.

4. Build a Referral Relationship with a Peptide-Knowledgeable Medical Provider

Find a physician or other appropriately licensed medical provider who understands peptide medicine, follows the evolving evidence, knows the regulatory environment, and is willing to collaborate with you.

That creates a much stronger model for patient care: The chiropractor identifies the patient’s needs, recognizes when peptide therapy might be helpful, educates the patient, refers when appropriate, and remains involved in the patient’s overall care.

References:

Food and Drug Administration. Pharmacy Compounding Advisory Committee Meeting, July 23–24, 2026. U.S. Food and Drug Administration; 2026. Available at: https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026.

Food and Drug Administration. FDA Briefing Document: Pharmacy Compounding Advisory Committee Meeting, July 23–24, 2026. U.S. Food and Drug Administration; 2026. Available at: FDA briefing document.

Zhou L, et al. Review of clinical pharmacology information for peptides found in US FDA drug labeling. J Clin Pharmacol. 2025. doi:10.1002/jcph.70047. Available at: PubMed.

Muttenthaler M, King GF, Adams DJ, Alewood PF. Trends in peptide drug discovery. Nat Rev Drug Discov. 2021;20(4):309-325. doi:10.1038/s41573-020-00135-8. Available at: https://doi.org/10.1038/s41573-020-00135-8.

Lee E, Burgess K. Safety of intravenous infusion of BPC157 in humans: a pilot study. Altern Ther Health Med. 2025;31(5):20-24. PMID: 40131143. Available at: PubMed.

Calcei JG, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. 2025. PMID: 40756949. Available at: PubMed.

Dudek A, et al. Multifunctionality and possible medical application of the BPC 157 peptide—literature and patent review. 2025. PMID: 40005999. Available at: PubMed.

Getting SJ, Schiöth HB, Perretti M. Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. J Pharmacol Exp Ther. 2003;306(2):631-637. doi:10.1124/jpet.103.051623. Available at: PubMed.

Brzoska T, Luger TA, Maaser C, Abels C, Böhm M. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, anti-inflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr Rev. 2008;29(5):581-602. PMID: 18612139. Available at: PubMed.

Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454. doi:10.1016/j.cmet.2015.02.009. Available at: PubMed.

Yoon SH, Yuan F, Zhu X, et al. Systemic MOTS-c levels are increased in adults with obesity in association with metabolic dysregulation and remain unchanged after weight loss. J Clin Transl Endocrinol. 2026;43:100429. doi:10.1016/j.jcte.2025.100429. Available at: PubMed.

Skvortsova VI, Stakhovskaia LV, Gubskii LV, et al. Effectiveness of Semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study). Zh Nevrol Psikhiatr Im S S Korsakova. 2001. PMID: 11517472. Available at: PubMed.

Teli B, et al. Semaglutide and follow-on peptide therapeutics: balancing innovation, regulation, and clinical outcomes. Cureus. 2026. doi:10.7759/cureus.108999. Available at: PubMed.

Usmani SS, Bedi G, Samuel JS, et al. THPdb: database of FDA-approved peptide and protein therapeutics. PLoS One. 2017;12(7):e0181748. doi:10.1371/journal.pone.0181748. Available at: https://doi.org/10.1371/journal.pone.0181748.

Grand View Research. Peptide Therapeutics Market Size, Share & Trends Analysis Report, 2026–2033. Grand View Research; 2026. Available at: https://www.grandviewresearch.com/industry-analysis/peptide-therapeutics-market